8-K: Karyopharm Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Clinical Program Updates

Karyopharm reports $145 million in total revenue for 2024, updates Phase 3 XPORT-EC-042 trial, and anticipates top-line data from the SENTRY trial in the second half of 2025.

Summary

• Karyopharm Therapeutics Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Total revenue for 2024 was $145 million, with U.S. XPOVIO net product revenue reaching $113 million.
• The company is updating its Phase 3 XPORT-EC-042 trial for endometrial cancer, focusing on specific patient populations and expecting top-line data in mid-2026.
• Karyopharm anticipates top-line data from the Phase 3 SENTRY trial for myelofibrosis in the second half of 2025.
• The company provides full-year 2025 total revenue guidance of $140 million to $155 million, including U.S. XPOVIO net product revenue guidance of $115 million to $130 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company highlights positive clinical developments and provides revenue guidance, there are also challenges related to trial modifications, competition, and funding concerns. The financial results show a slight decrease in total revenue and a decrease in cash position.

Positives

• U.S. XPOVIO net product revenue increased slightly from $112 million in 2023 to $113 million in 2024.
• Demand for XPOVIO was consistent in 2024 versus 2023, with demand growth in the second half of 2024 in both the community setting and the academic setting.
• Expanded global patient access for selinexor in 2024 with favorable reimbursement decisions in the United Kingdom, France, Italy, China and South Korea and additional regulatory approvals in UAE, Kuwait, China, Malaysia, Turkey, Thailand, and South Korea in various indications, increasing the number of countries where selinexor is now approved in more than 45 countries.
• The company completed enrollment of the Phase 3 XPORT-MM-031 trial in multiple myeloma.
• Net loss decreased from $143.1 million in 2023 to $76.4 million in 2024.

Negatives

• Total revenue decreased slightly from $146 million in 2023 to $145.2 million in 2024.
• License and other revenue decreased from $34 million in 2023 to $32.4 million in 2024.
• Cash, cash equivalents, restricted cash and investments decreased from $192.4 million as of December 31, 2023 to $109.1 million as of December 31, 2024.
• XPOVIO net product revenue was impacted year-over-year by higher gross-to-net adjustments in 2024, driven primarily by increased 340B discounts and Medicare rebates.

Risks

• The evolving treatment landscape in endometrial cancer, particularly the approval of checkpoint inhibitors, necessitates modifications to the Phase 3 XPORT-EC-042 trial.
• The company's ability to fund its operations is dependent on XPOVIO net product sales and revenue from license agreements.
• There is a risk that clinical trials may not be successful or that regulatory approvals may not be obtained.
• The company faces competition in the multiple myeloma marketplace.
• The company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO net product sales, as well as revenue generated from its license agreements, will be sufficient to fund its planned operations into the first quarter of 2026.

Future Outlook

Karyopharm expects total revenue to be in the range of $140 million to $155 million for full year 2025, with U.S. XPOVIO net product revenue in the range of $115 million to $130 million. The company anticipates top-line data from the Phase 3 SENTRY trial in the second half of 2025 and from the updated Phase 3 XPORT-EC-042 trial in mid-2026.

Management Comments

• Richard Paulson, President and Chief Executive Officer of Karyopharm, stated that the company remains focused on redefining the standard of care in myelofibrosis and leveraging commercialization capabilities in multiple myeloma.
• Richard Paulson also mentioned the updated plans for the Phase 3 trial in endometrial cancer, focusing on the TP53 wild-type pMMR population.

Industry Context

Karyopharm is operating in a competitive oncology market, particularly in multiple myeloma, where it faces competition from established therapies. The company is also navigating the evolving treatment landscape in endometrial cancer, where the approval of checkpoint inhibitors has changed the standard of care. The company is focusing on specific patient populations and combination therapies to address unmet needs in these areas.

Comparison to Industry Standards

• The Phase 1 trial data evaluating the combination of selinexor 60 mg plus ruxolitinib in JAKi nave myelofibrosis patients, demonstrated that 79% of patients in the intent to treat population (n=14) achieved SVR35 and an average Abs-TSS improvement of 18.5 points in the efficacy evaluable population (n=9), at week 24 relative to baseline.
• These data suggest that the combination is favorable compared to historical ruxolitinib monotherapy data which indicates that less than half of patients achieve SVR35 and an Abs-TSS improvement of 11 to 14 points1.
• The reference to the Phase 3 MANIFEST trial and Phase 3 TRANSFORM-1 trial provides a benchmark for comparing the efficacy of Karyopharm's combination therapy to ruxolitinib monotherapy.

Stakeholder Impact

• Shareholders: The announcement provides information on the company's financial performance and clinical development programs, which may impact their investment decisions.
• Employees: The company's financial performance and strategic direction may impact employee morale and job security.
• Patients: The clinical development programs and potential regulatory approvals of selinexor may provide new treatment options for patients with cancer.
• Partners: The company's partnerships for commercializing selinexor in ex-U.S. territories may be impacted by the company's financial performance and regulatory developments.

Next Steps

• Complete enrollment of the Phase 3 SENTRY trial in the first half of 2025.
• Report preliminary data on a subset of participants in the 60 mg cohort from the Phase 2 SENTRY-2 trial in the first half of 2025.
• Report top-line results from the Phase 3 SENTRY trial in the second half of 2025.
• Continue to enroll patients into the Phase 3 XPORT-EC-042 trial.
• Provide an update on the Phase 3 XPORT-MM-031 trial pending ongoing engagement with regulatory agencies.

Key Dates

Keywords

Karyopharm, XPOVIO, selinexor, myelofibrosis, endometrial cancer, multiple myeloma, financial results, clinical trials, revenue, pharmaceutical